Board of Directors: (Includes Founders, Jenny Corbin and Larry Horn)
Phoebe A. Wood, Executive Chair of the Board. Ms. Wood is a principal of CompaniesWood, a consulting firm that specializes in advising and investing in early-stage ("angel") investments. She recently served as Vice Chairman and Chief Financial Officer of Brown-Forman Corporation, where she was responsible for the corporate development, controller, treasury, investor relations, tax, information technology, and internal audit departments.Before joining Brown-Forman, Ms. Wood served as Vice President and Chief Financial Officer of Motorola's telecom subsidiary, Propel, Inc. Prior to joining Motorola, Phoebe enjoyed a career of over 20 years with the Atlantic Richfield Company (now BP).
Ms. Wood was graduated cum laude by Smith College and holds an MBA from UCLA. She is a director of Leggett & Platt Corporation, Invesco Ltd., and Coca-Cola Enterprises, Inc. Previously, Ms. Wood served on the Board of Directors at OshKosh B'Gosh. She is a Trustee of the University of Louisville, The Gheens Foundation, and the American Printing House for the Blind. She is a former trustee of Smith College and Louisville Collegiate School.
Butch Mercer is President and CEO of BioMark Inc., an international business and executive coaching firm, focused on bringing valued-added services in the areas of executive management and strategic business issues for early and mid-stage companies, technology concepts, venture capital firms and government agencies. Prior to BioMark, he was the Global Business Leader for Dow AgroSciences, Animal Health and Food Safety efforts. This responsibility included a focused effort on successfully bringing the plantmade technology platform to scientific and commercial success for Dow Agro-Sciences, which resulted in the company obtaining the world's first registration for a Plant-Cell-Produced Vaccine in less than five year's time. Mr. Mercer has negotiated over $3.6B dollars worth of agreements and managed fully integrated businesses up to $200 million dollars in his career. His career has spanned more than 30 years in the Animal Health industry, including the past 20 years with the related biotechnology industry. He is cofounder of Rimedion Inc., a gene therapy start-up company. Previously he has served as Chairman and CEO of Xylogenics, a renewable energy company, Vice President of the Indiana 4-H Foundation, been a member of the Board of Directors of the Animal Health Institute and also its Affiliate Chairman. He is a former Board member of SemBioSys Corporation, a publicly traded biotechnology company. He is also a former board member of Internous Inc., a data-mining firm and has served as Vice Chairman of the BIO Plant-Made Pharmaceutical Committee. He also served four years as a Member of the Dow Chemical Venture Capital Committee for Life Sciences. He is a member of the National Association of Corporate Directors and the Licensing Executive Society.
Mr. Mercer grew up on a livestock and grain operation in central Indiana and attended Purdue University in Animal Sciences.
Kent R. Van Kampen DVM, PhD served as the Chief Operating Officer and Chief Executive Office of Vaxin, Inc. before retiring. Dr. Van Kampen has a wealth of experience in the field of vaccinology especially in the research, development and commercialization of vaccines. From 1985-91 he served as the Chief Executive Officer of Virogenetics, Troy, New York, a subsidiary of Institut Merieux, Lyon, France. At Virogenetics, a number of recombinant animal vaccines were designed that are currently marketed by Merial. He was instrumental in obtaining a license from the USDA for Raboral, an orally active rabies vaccine used to vaccinate wildlife. At ImmunoMed, Inc. Tampa, Florida he helped license one of the first immunomodulators used in large animals. From 1976 to 1980, Dr. Van Kampen served as Head of the Department of Animal, Dairy, and Veterinary Sciences at Utah State University. From 1980 to 1984, he headed of the Physiological Research Laboratory and was Director of The Implantable Drug Delivery Device program forMedtronic, Minneapolis, Minnesota. Dr. Van Kampen serves as the Chairman of the Board of Directors of ImmunoMed Corp and as a Director of Cognitive Engineering, SVK Laboratories, HMV Corp. and The Van Kampen Group Inc. He also serves as a Member ofthe Scientific Advisory Board at Qu Biologics Inc., Vancouver, BC, Canada Dr. Van Kampen is a Co-editor of a book and the author of more than 70 scientific publications. In 1994, Dr. Van Kampen was awarded an Honorary Doctorate Degree from Utah State University. He is a Diplomate of the American College of Veterinary Pathologists and holds a Doctorate Degree in Veterinary Medicine from Colorado State University and a Ph.D. in Comparative Pathology from the University of California, Davis.